Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer BioSpaceA triplet regimen comprising Merck's Welireg and PD-1 blockbuster Keytruda and Eisai's Lenvima flopped in a Phase 3 renal cell carcinoma trial.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioSpace A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial. Clinical DataOncologyRead full story Post navigation Previous: Novo Nordisk preps filings for sickle cell drug etavopivatNext: Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
